Related Experiment Videos

Treatment of infantile spasms with intravenous gamma-globulins

B Echenne1, O Dulac, M J Parayre-Chanez

  • 1Unité de Neuropédiatrie, Centre Gui de Chauliac, Montpellier, France.

Brain & Development
|September 1, 1991
PubMed

Insights

High-dose intravenous immunoglobulin (IVIg) therapy showed disappointing results for most children with infantile spasms. However, some patients experienced significant clinical and electroencephalographic improvements, suggesting potential as an auxiliary treatment.

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • Infantile spasms (IS) are a severe epilepsy syndrome in infants.
  • West syndrome and Lennox-Gastaut syndrome are specific epilepsy classifications.
  • Current treatments for IS have limitations, prompting investigation into novel therapies.

Purpose of the Study:

  • To evaluate the efficacy of high-dose intravenous immunoglobulin (IVIg) as a treatment for infantile spasms.
  • To assess potential correlations between treatment outcomes and immunological markers.

Main Methods:

  • A prospective study involving 23 children diagnosed with infantile spasms.
  • Administration of high-dose intravenous gammaglobulins (IVIg).
  • Clinical and electroencephalographic assessments were performed to monitor treatment response.

Main Results:

  • No significant improvement was observed in 15 out of 23 patients.
  • Transient clinical and/or electroencephalographic improvement occurred in 3 patients.
  • Complete normalization was achieved in 5 patients, with 4 having severe brain lesions. No correlation with immunological abnormalities was found.

Conclusions:

  • Overall therapeutic results of IVIg for infantile spasms were disappointing.
  • However, the occurrence of notable improvements in a subset of patients suggests IVIg may serve as an effective auxiliary treatment.
  • Further research is warranted to identify patient subgroups most likely to benefit from IVIg therapy.

Related Concept Videos